Thank you for donating!

You can donate using the following services.


  1. 30.09.20

    IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C

    Read more
  2. 16.09.20

    Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C

    Read more
  3. 16.09.20

    NPUK Annual Family Conference & Interactive Workshop 2020 - FULL PROGRAMME

    We are pleased to share the full programme for this year's Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases, which will be the very first digital Conference we have held. Despite this we are sure it will be an informative, supportive, and entertaining weekend for all of the friends and families within our community...

    Read more
  4. 08.09.20

    Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    Read more
  5. 28.08.20

    Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP with $1.0 Million

    GAINESVILLE, FL – (BusinessWire) – August 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors...

    Read more